Episode #5
Innovators at the Table: The Right Treatment for the Right Patient
Send us Fan Mail How do you answer one of the most consequential questions in cancer care: not just whether a patient has cancer, but which treatment will actually help them? For years, the answer was hidden in plain sight. In this episode of PathPulse, part of our Behind the Summit series spotlighting the sponsors of the Digital Diagnostic Summit, host Bianca Collings sits down with Laura Chang, Chief Product Officer at Artera AI. Founded by a radiation oncologist and a Stanford-trained AI scientist, Artera built the first test that uses AI to read digital pathology images and clinical data together to predict whether a specific patient will benefit from hormone therapy. Their work is so groundbreaking that it’s already written into the NCCN Clinical Practice Guidelines for Prostate Cancer as the recommended standard of care. Laura discusses her journey from a one-person startup to leading product at Artera, the critical need to solve overtreatment in prostate and breast cancers, and how digital pathology makes precision oncology faster and more accessible than traditional genomics. She also shares a deeply personal story of a pathologist friend who relied on Artera's test for his own cancer diagnosis when traditional testing fell short. If you’ve ever wondered how AI is turning standard glass slides into personalized treatment roadmaps, this one’s for you. Artera was one of the sponsors of the 2026 Digital Diagnostic Summit at The St. Regis Deer Valley in Park City, Utah. Get on the 2027 Summit waiting list to meet innovators like this next year during 3 days of sessions, hands-on conversation, and mountain-air networking with the people mapping diagnostic innovation to patient impact. [Register now →] Watch on Youtube Submit questions for our future recordings here: https://lumeadigital.com/ask-a-pathologist-podcast/ Sponsored by the Digital Diagnostic Summit and Lumea.
